$CBRS

Comparing Cerebras Systems (NASDAQ:CBRS) & Aeluma (NASDAQ:ALMU)

MarketBeat.com compares Cerebras Systems (CBRS) and Aeluma (ALMU). It reports Aeluma has a consensus price target of $25.33 (about 4% upside) and a stronger consensus rating. The article also states Cerebras has higher revenue and earnings, while profitability metrics are compared via net margin and returns on equity/assets.

Original reporting
Published May 27, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Comparing Cerebras Systems (NASDAQ:CBRS) & Aeluma (NASDAQ:ALMU) — source image
Decision brief

The 30-second read

$CBRSBullishLow
01

Why it matters

Trading relevance is primarily sentiment/positioning from analyst-target framing (ALMU) and a hyperscaler deployment narrative (CBRS), rather than a discrete new corporate action.

02

Market read

Investors may use the article to adjust relative positioning between AI infrastructure (CBRS) and compound semiconductor exposure (ALMU), but it lacks a clear new catalyst.

03

What to watch

Execution risk (CBRS wafer-scale yield/cost and customer ramp) and potential cyclicality/competition in compound semiconductors (ALMU) are not quantified; valuation tables are referenced but not numerically detailed here.

Relevance 6/10Timing: No event date (earnings/contract/regulatory decision) is provided; impact is mainly from analyst-target framing.

Background

The article compares Cerebras Systems (CBRS) and Aeluma (ALMU) across earnings/valuation/profitability and includes a narrative on Cerebras’ wafer-scale AI inference speed and Aeluma’s analyst price target.

Company-level read

Ticker impact

$CBRSBullishMedium confidence
Context

The article profiles Cerebras’ wafer-scale AI inference claims and cites a binding AWS term sheet to deploy its chips in hyperscaler data centers.

Expected impact

Near-term price reaction likely limited; any upside would depend on how investors weigh the AWS deployment claim versus valuation and execution risk.

Evidence & confidence

The only concrete, company-specific catalyst-like item is the AWS binding term sheet; the rest is a general business description and a head-to-head comparison.

$ALMUBullishLow confidence
Context

The article states Aeluma has a consensus price target of $25.33 and implies analysts view it more favorably than Cerebras.

Expected impact

Potential for short-term sympathy/mean-reversion buying if traders react to the target/upside framing.

Evidence & confidence

The article provides ratings/target context but no earnings, guidance, contract, or regulatory update; price impact is therefore uncertain.

Market effects

Highlights investor attention on AI infrastructure (CBRS) and compound semiconductor/optoelectronics exposure (ALMU), but without new sector-wide policy or demand shock.

Limited; both companies are US-based and the article does not cite regional procurement or regulatory changes.

Limited; the AI infrastructure TAM figures are cited but not tied to a new global order, trial, or regulation.

Counterpoint

The piece is a comparison article with heavy marketing language and no verifiable new financial datapoints; analyst targets can lag fundamentals and may not drive sustained repricing.

Key entities

  • Cerebras Systems

    Wafer-scale AI inference provider; article cites OpenAI selection and an AWS binding term sheet to deploy in AWS data centers.

  • Aeluma

    Optoelectronic/electronic devices company; article cites a consensus price target of $25.33 and relative analyst favorability.

  • Amazon Web Services

    Cited as signing a binding term sheet with Cerebras for deployment in its own data centers.

  • OpenAI

    Cited as selecting Cerebras as a fast inference solution for Codex-Spark users.

Related articles

High

Why is Aeluma stock surging today?

Aeluma stock rose 7.0% in pre-market trading after announcing a partnership with Sumitomo Chemical Advanced Technologies to develop and manufacture photonics wafers for AI datacom. The company is set to report Q4 and full-year 2026 earnings on September 16. The sole analyst's price target of $30.50 suggests significant upside from current levels.

$CBRSMedAI 8/10

Cerebras Has a $25.4 Billion Backlog, and One OpenAI Agreement Is Behind Much of It

Cerebras Systems reported Q2 adjusted revenue of $209.9M, up 103% YoY, with a $25.4B backlog driven by an OpenAI agreement. The company raised its full-year outlook to $880M-$890M. OpenAI's deal accounts for most of the backlog, with revenue recognition expected over several years. Cerebras' stock is down 44% from its 52-week high, trading at a market cap of ~$51B.

$CBRSHighAI 8/10

CBRS Stock Surges 68% On Nasdaq Debut: Cathie Wood's ARK Buys Shares While Trimming TSMC, AMD

Cerebras Systems (CBRS) shares surged 68% on their Nasdaq debut, closing at $311.07, with a market cap of $95B. ARK ETFs bought 105,616 shares, while trimming stakes in TSMC and AMD. The IPO raised $5.6B, with strong demand highlighting investor interest in AI hardware. CBRS reported $510M in 2023 sales, up from $290.3M in 2024, and partners with OpenAI, Meta, AWS, and IBM.

$CBRSMed

CBRS Stock Slides As Cerebras Ramps AI Capacity And Growth

Cerebras Systems Inc. (CBRS) stock rose 10.73% on September 4, 2026, driven by investor optimism around AI chip adoption. The company reported Q2 2026 revenue of $510M and a loss of $451M, with a high price-to-sales multiple of 117x. Morgan Stanley reiterated its overweight rating, citing strong AI demand and partnerships. CBRS faces execution risks due to high spending on AI capacity expansion.

$CBRSMed

Cerebras Systems Stock Slides As Wall Street Backs Aggressive AI Expansion

Cerebras Systems Inc. (CBRS) stock rose 10.91% on September 4, 2026, driven by bullish sentiment around its AI chip advancements. The company reported quarterly revenue of $180.1M and a net loss of $450.5M, with a price-to-sales ratio of 117.36. Morgan Stanley reiterated its overweight rating, citing surging AI inference demand and expected revenue growth. However, risks include execution challenges in data center expansion and profitability concerns.